Earendil Labs Taps WuXi Biologics to Accelerate Complex Antibody and ADC Pipeline

New updates have been reported about Earendil Labs.

Earendil Labs has entered a strategic collaboration with WuXi Biologics to advance and manufacture multiple bispecific and multispecific antibodies and antibody-drug conjugate candidates across its autoimmune and oncology pipeline. Under the agreement, WuXi Biologics will deliver integrated services from cell line and process development through formulation and GMP production, with the goal of compressing regulatory timelines and ensuring reliable chemistry, manufacturing and controls execution for global clinical programs.

The partnership is intended to convert Earendil Labs’ AI-driven protein engineering into scalable clinical and, ultimately, commercial assets by leveraging WuXi Biologics’ platforms for complex biologics and high-dose or subcutaneous delivery. Earendil’s CEO Jian Peng and President and co-CEO Zhenping Zhu said the deal strengthens the company’s ability to move a growing, multi-asset pipeline toward key clinical milestones and build differentiated next-generation immunotherapies.